AKT1 and Miyoshi myopathy: Indeed, the treatment of MM cells with LY294002, an inhibitor of phosphoinositide 3-kinase, decreased the activation of Akt, along with cell adhesion and the cell survival rates after treatment with chemotherapy drugs.